Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Prof Shoumo Bhattacharya who has secured a £1m programme grant from the British Heart Foundation to further his research on the use of novel anti-inflammatories in cardiovascular disease.

© Shutterstock

Inflammation plays an important role in heart attack, myocarditis, atherosclerosis and stroke, and is driven by chemokines, which recruit white blood cells to injured tissues. Unfortunately, sometimes the white blood cells start attacking healthy tissues and organs. It has not been possible to invent drugs that block the chemokine network in inflammation. Ticks, however, have evolved proteins in their saliva called evasins that block chemokines and inflammation very effectively. Prof Bhattacharya and his team have invented a technology, "Bug-to-Drug", which allows them to very quickly identify new evasins from tick saliva gland genes by inserting them into yeast. They have identified over 30 new evasins from different tick species, and have shown that they precisely bind certain subclasses of chemokines.

The team will develop evasins as precision treatments for inflammation, so that they hit only those chemokines relevant to a particular inflammatory heart disease and understand how these evasins work. We will study some of the new evasins in models of myocarditis, a deadly disease that leads to heart failure, and for which there is no effective treatment.

The team recently published new results in Scientific Reports on their genetically engineered evasins. They 'synthetically created the most effective of evasins from two different tick species and genetically fused them to create a preliminary drug that successfully prevented inflammation in laboratory tests'.

Speaking to The I Paper about the recent results, Prof Bhattacharya said “We’re really excited about this. This is a new class of potential drug which can target 80 to 90 per cent of the inflammation-causing chemicals produced by the body in diseases such as arthritis, pancreatitis, colitis and Crohn’s disease.”

This work builds on an RDM pump Priming Award to Prof Bhattacharya and Associate Prof Adam Mead. The work has gone on to leverage £1.8m funding.

“These little creatures could hold the secret to new treatments for a wide range of heart and circulatory diseases caused by inflammation,” said Professor Jeremy Pearson, Associate Medical Director at the British Heart Foundation. “This is an exciting new approach which could ultimately save lives,” he added.

Read ‘Genetically engineered two-warhead evasins provide a method to achieve precision targeting of disease-relevant chemokine subsets’ in Scientific Reports online here.

 

 

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with communications@rdm.ox.ac.uk

 

Similar stories

James Davies named as Lister Research Prize Fellow

James Davies has been named as one of eight researchers selected for the 2022 Fellowship scheme.

Understanding the interplay of dietary iron, anaemia and the immune system

Four related projects aim to unravel how the iron we eat shapes how the immune system develops and responds to vaccines.

Six new Associate Professor titles at RDM

Graham Collins, Betty Raman, Susie Shapiro, Christopher Toepfer, Stephen Twigg, and Adam Wilkinson have all been awarded Associate Professor titles

Two NHSBT research units launch at RDM

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford, with two of them led by RDM researchers.